Drugs / E6007
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03444818 | Apr → Jun 2018 | — | EA Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02268838 | Oct 2014 → Jul 2015 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01221818 | Sep 2010 → Oct 2011 | inflammatory bowel disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03018054 | Nov 2016 → Apr 2019 | ulcerative colitis | EA Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E6007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02268838 ↗ |
| Route | Oral | “single oral ascending doses of E6007” NCT01221818 ↗ |